Hi Everyone - partly inspired by attending the recent EA Global London conference a couple of weeks ago, I've written a CGD Blog with some thoughts on EA's approach to prioritisation and methods in health economics (specifically Health Technology Assessment). This is a link post and as CGD staff I have to post on our platform, but since the key target audience is EAs, I'd be delighted to hear thoughts from this community. I'll be sure to monitor the comments section and perhaps the discussion will feed into future work.
The differences between EA and health econ I highlight include:
1. Approaches to generalising cost-effectiveness evidence
2. Going beyond cost-effectiveness in determining value
3. Deliberative appraisal
4. Institutionalisation of a participatory process
Please click through for the full blog.
Ok gotcha this time. Similar to some of the response to Jason below I would say that the assessment of value and the assessment of gaps etc are separate steps. We shouldn’t think about adopting a value framework because it allows us to find a practical niche. I suppose it does beg the question; whose value framework should we use? I don’t have that answer, but I do think that it links to the 4th difference in my blog; about institutionalisation and participation.
Btw, you imply that the rest of the aid landscape uses this HTA-like approach to prioritisation.. Sadly this is certainly not the case! I worked in the UK Department for International Development for several years, in a team that was tasked with providing evidence to the rest of the organisation. We did our best but it was a long way from perfect. Indeed I do see a significant opportunity for EA movement and organisations to influence other donors to take a more systematic, evidence-informed approach. For me this absolutely does mean using cost-effectiveness - but it means using it not in a blunt way but as part of an appropriate process and so that - wherever possible - we work with, not around, local systems and institutions.